Skip to main content
PMC home page
Virologica Sinica logoLink to Virologica Sinica
. 2013 Apr 11;28(2):109–115. doi: 10.1007/s12250-013-3303-z

Potent T cell responses induced by single DNA vaccine boosted with recombinant vaccinia vaccine

Lianxing Liu 13303,23303, Chao Qiu 33303, Yang Huang 33303, Jianqing Xu 33303,✉, Yiming Shao 13303,23303,✉
PMCID: PMC8208324  PMID: 23575733

Abstract

Plasmid DNA, an effective vaccine vector, can induce both cellular and humoral immune responses. However, plasmid DNA raises issues concerning potential genomic integration after injection. This issue should be considered in preclinical studies. Tiantan vaccinia virus (TV) has been most widely utilized in eradicating smallpox in China. This virus has also been considered as a successful vaccine vector against a few infectious diseases. Potent T cell responses through T-cell receptor (TCR) could be induced by three injections of the DNA prime vaccine followed by a single injection of recombinant vaccinia vaccine. To develop a safer immunization strategy, a single DNA prime followed by a single recombinant Tiantan vaccinia (rTV) AIDS vaccine was used to immunize mice. Our data demonstrated that one DNA prime/rTV boost regimen induced mature TCR activation with high functional avidity, preferential T cell Vβ receptor usage and high sensitivity to anti-CD3 antibody stimulation. No differences in T cell responses were observed among one, two or three DNA prime/rTV boost regimens. This study shows that one DNA prime/rTV boost regimen is sufficient to induce potent T cell responses against HIV.

Keywords: HIV, Vaccine, T cell responses, Prime-boost regimen

Footnotes

Foundation items: This research was supported by the China Comprehensive Integrated Programs for Research on AIDS (CIPRA, U19AI51915), by the National Key Projects on Major Infectious Diseases (Grant No. 2008ZX10001-010, 2012ZX10001-008), and by the National Natural Science Foundation of China (31000413).

Contributor Information

Jianqing Xu, Phone: +86-21-37990333-7335, FAX: +86-21-57247094, Email: jianqingxu2008@gmail.com.

Yiming Shao, Phone: +86-10-58900982, FAX: +86-10-58900980, Email: yshao2008@gmail.com.

References

  1. Alarcon J B, Waine G W, McManus D P. DNA vaccines: technology and application as anti-parasite and anti-microbial agents. Adv Parasitol. 1999;42:343–410. doi: 10.1016/S0065-308X(08)60152-9. [DOI] [PubMed] [Google Scholar]
  2. Betts M R, Nason M C, West S M, De Rosa S C, Migueles S A, Abraham J, Lederman M M, Benito J M, Goepfert P A, Connors M, Roederer M, Koup R A. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006;107(12):4781–4789. doi: 10.1182/blood-2005-12-4818. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Buchinder S P, Mehrotra D V, Duerr A, Fitzgerald D W, Mogg R, Li D, Gilbert P B, Lama J R, Marmor M, Del Rio C, McElrath M J, Casimiro D R, Gottesdiener K M, Chodakewitz J A, Corey L, Robertson M N, Step Study Protocol Team Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372(9653):1881–1893. doi: 10.1016/S0140-6736(08)61591-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Excler J L, Plotkin S. The prime-boost concept applied to HIV preventive vaccines. AIDS. 1997;11(SupplA):S127–137. [PubMed] [Google Scholar]
  5. Gu S, Huang T, Miao Y, Ruan L, Zhao Y, Han C, Xiao Y, Zhu J, Wolf H. A preliminary study on the immunogenicity in rabbits and in human volunteers of a recombinant vaccinia virus expressing Epstein-Barr virus membrane antigen. Chin Med Sci J. 1991;6(4):241–243. [PubMed] [Google Scholar]
  6. Guo K J, Ruan L, Wang X J, Yi Y, Liu C B, Ren Y H, Zhang Y C, Liu X H, Gao S J, Yang J W, Zhu J M. The immunological effect of recombinant vaccinia virus (VMS11HAV25) expressing hepatitis A antigen in humans. Chin J Microbiol Immunol. 1992;12(3):137–140. [Google Scholar]
  7. Hel Z, Tsai W P, Thornton A, Nacsa J, Giuliani L, Tryniszewska E, Poudyal M, Venzon D, Wang X, Altman J, Watkins D I, Lu W, von Gegerfelt A, Felber B K, Tartaglia J, Pavlakis G N, Franchini G. Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. J Immunol. 2001;167(12):7180–7191. doi: 10.4049/jimmunol.167.12.7180. [DOI] [PubMed] [Google Scholar]
  8. Huang X, Xu J, Ren L, Qiu C, Zhang N, Liu L X, Wan Y M, Peng H, Shao Y M. Intranasal priming with HIV DNA vaccine and systemic boosting with recombinant vaccinia induce vigorous immune responses: experiment with mice. Zhonghua Yi Xue Za Zhi. 2006;86(44):3109–3113. [PubMed] [Google Scholar]
  9. Ledwith B J, Manam S, Troilo P J, Barnum A B, Pauley C J, Griffiths T G, 2nd, Harper L B, Schock H B, Zhang H, Faris J E, Way P A, Beare C M, Bagdon W J, Nichols W W. Plasmid DNA vaccines: assay for integration into host genomic DNA. Dev Biol (Basel) 2000;104:33–43. [PubMed] [Google Scholar]
  10. Martin T, Parker S E, Hedstrom R, Le T, Hoffman S L, Norman J, Hobart P, Lew D. Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum Gene Ther. 1999;10:759–768. doi: 10.1089/10430349950018517. [DOI] [PubMed] [Google Scholar]
  11. Montgomery D L, Ulmer J B, Donnelly J J, Liu M A. DNA vaccines. Pharmacol Ther. 1997;74(2):195–205. doi: 10.1016/S0163-7258(97)82003-7. [DOI] [PubMed] [Google Scholar]
  12. Potter S J, Lacabaratz C, Lambotte O, Perez-Patrigeon S, Vingert B, Sinet M, Colle J H, Urrutia A, Scott-Algara D, Boufassa F, Delfraissy J F, Thèze J, Venet A, Chakrabarti L A. Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol. 2007;81(24):13904–13915. doi: 10.1128/JVI.01401-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ramshaw I A, Ramsay A J. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today. 2000;21(4):163–165. doi: 10.1016/S0167-5699(00)01612-1. [DOI] [PubMed] [Google Scholar]
  14. Ren L, Qiu C, Huang X G, Pan X, Xu J Q, Shao Y M. Construction and immunogenecity analysis of HIV-1 B_ gag-env DNA vaccine. Chin J Microbiol Immunol. 2006;26(7):654–658. [Google Scholar]
  15. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil J G, Francis D P, Stablein D, Birx D L, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb M L, Michael N L, Kunasol P, Kim J H, MOPH-TAVEG Investigators Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209–2220. doi: 10.1056/NEJMoa0908492. [DOI] [PubMed] [Google Scholar]
  16. Robinson H L, Pertmer T M. DNA vaccines for viral infections: basic studies and applications. Adv Virus Res. 2000;55:1–74. doi: 10.1016/S0065-3527(00)55001-5. [DOI] [PubMed] [Google Scholar]
  17. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, Barré-Sinoussi F, Delfraissy J F, Sinet M, Pancino G, Venet A, Agence Nationale de Recherches sur le Sida EP36 HIV Controllers Study Group HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A. 2007;104(16):6776–6781. doi: 10.1073/pnas.0611244104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Saez-Cirion A, Sinet M, Shin S Y, Urrutia A, Versmisse P, Lacabaratz C, Boufassa F, Avettand-Fènoël V, Rouzioux C, Delfraissy JF, Barré-Sinoussi F, Lambotte O, Venet A, Pancino G, ANRS EP36 HIV Controllers Study Group Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol. 2009;182:7828–7837. doi: 10.4049/jimmunol.0803928. [DOI] [PubMed] [Google Scholar]
  19. Schneider J, Gilbert S C, Blanchard T J, Hanke T, Robson K J, Hannan C M, Becker M, Sinden R, Smith G L, Hill A V. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med. 1998;4(4):397–402. doi: 10.1038/nm0498-397. [DOI] [PubMed] [Google Scholar]
  20. Shiver J W, Fu T M, Chen L, Casimiro D R, Davies M E, Evans R K, Zhang Z Q, Simon A J, Trigona W L, Dubey S A, Huang L, Harris V A, Long R S, Liang X, Handt L, Schleif W A, Zhu L, Freed D C, Persaud N V, Guan L, Punt K S, Tang A, Chen M, Wilson K A, Collins K B, Heidecker G J, Fernandez V R, Perry H C, Joyce J G, Grimm K M, Cook J C, Keller P M, Kresock D S, Mach H, Troutman R D, Isopi L A, Williams D M, Xu Z, Bohannon K E, Volkin D B, Montefiori D C, Miura A, Krivulka G R, Lifton M A, Kuroda M J, Schmitz J E, Letvin N L, Caulfield M J, Bett A J, Youil R, Kaslow D C, Emini E A. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency virus immunity. Nature. 2002;415(6869):331–335. doi: 10.1038/415331a. [DOI] [PubMed] [Google Scholar]
  21. Vilalta A, Mahajan R K, Hartikka J, Rusalov D, Martin T, Bozoukova V, Leamy V, Hall K, Lalor P, Rolland A, Kaslow D C. I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration. Hum Gene Ther. 2005;16:1143–1150. doi: 10.1089/hum.2005.16.1143. [DOI] [PubMed] [Google Scholar]
  22. Wang Z, Troilo P J, Wang X, Griffiths T G, Pacchione S J, Barnum A B, Harper L B, Pauley C J, Niu Z, Denisova L, Follmer T T, Rizzuto G, Ciliberto G, Fattori E, Monica N L, Manam S, Ledwith B J. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther. 2004;11:711–721. doi: 10.1038/sj.gt.3302213. [DOI] [PubMed] [Google Scholar]
  23. Wolff J A, Malone R W, Williams P, Chong W, Acsadi G, Jani A, Felgner P L. Direct gene transfer into mouse musclein vivo. Science. 1990;247(4949Pt1):1465–1468. doi: 10.1126/science.1690918. [DOI] [PubMed] [Google Scholar]
  24. Xu J, Ren L, Huang X, Qiu C, Liu Y, Liu Y, Shao Y. Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes. AIDS. 2006;20(18):2293–2303. doi: 10.1097/QAD.0b013e328010ad0c. [DOI] [PubMed] [Google Scholar]
  25. Zhao K, Zhang Y H, Li H M. Medical Biology Product. 2nd ed. Beijing: People’s Medical Publishing House; 1995. [Google Scholar]

Articles from Virologica Sinica are provided here courtesy of Wuhan Institute of Virology, Chinese Academy of Sciences

RESOURCES